191 related articles for article (PubMed ID: 10101803)
1. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response.
Peller S
Semin Cancer Biol; 1998; 8(5):379-87. PubMed ID: 10101803
[TBL] [Abstract][Full Text] [Related]
2. Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang P; Kitchen-Smith I; Xiong L; Stracquadanio G; Brown K; Richter PH; Wallace MD; Bond E; Sahgal N; Moore S; Nornes S; De Val S; Surakhy M; Sims D; Wang X; Bell DA; Zeron-Medina J; Jiang Y; Ryan AJ; Selfe JL; Shipley J; Kar S; Pharoah PD; Loveday C; Jansen R; Grochola LF; Palles C; Protheroe A; Millar V; Ebner DV; Pagadala M; Blagden SP; Maughan TS; Domingo E; Tomlinson I; Turnbull C; Carter H; Bond GL
Cancer Res; 2021 Apr; 81(7):1667-1680. PubMed ID: 33558336
[TBL] [Abstract][Full Text] [Related]
3. Tumor-suppressor p53: implications for tumor development and prognosis.
Kirsch DG; Kastan MB
J Clin Oncol; 1998 Sep; 16(9):3158-68. PubMed ID: 9738588
[TBL] [Abstract][Full Text] [Related]
4. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
5. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
6. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
7. Antitumor mechanisms when pRb and p53 are genetically inactivated.
Zhu L; Lu Z; Zhao H
Oncogene; 2015 Aug; 34(35):4547-57. PubMed ID: 25486431
[TBL] [Abstract][Full Text] [Related]
8. p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi T
Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
[TBL] [Abstract][Full Text] [Related]
9. [The importance of a SNiP of the MDM2 gene to modulate the p53 pathway and the predisposition to cancer].
Larsen CJ
Bull Cancer; 2011 Jan; 98(1):10. PubMed ID: 21591298
[No Abstract] [Full Text] [Related]
10. The dual role of mutant p53 protein in chemosensitivity of human cancers.
Mueller H; Eppenberger U
Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
[TBL] [Abstract][Full Text] [Related]
11. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
12. [The tumor suppressor gene p53 (part 2). Applications in human pathology].
Martin A
Ann Pathol; 1995; 15(3):184-91. PubMed ID: 7639854
[No Abstract] [Full Text] [Related]
13. The p53 mutation "gradient effect" and its clinical implications.
Zambetti GP
J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
[TBL] [Abstract][Full Text] [Related]
14. Clinical applications of the p53 tumor suppressor gene.
Diamandis EP
Clin Chim Acta; 1995 Jun; 237(1-2):79-90. PubMed ID: 7664481
[TBL] [Abstract][Full Text] [Related]
15. Implications of the p53 tumor-suppressor gene in clinical oncology.
Chang F; Syrjänen S; Syrjänen K
J Clin Oncol; 1995 Apr; 13(4):1009-22. PubMed ID: 7707100
[TBL] [Abstract][Full Text] [Related]
16. [p53 as a molecular target for cancer therapy].
Ishioka C; Osada M; Gamo M; Kanamaru R
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
[TBL] [Abstract][Full Text] [Related]
17. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.
Martinez-Rivera M; Siddik ZH
Biochem Pharmacol; 2012 Apr; 83(8):1049-62. PubMed ID: 22227014
[TBL] [Abstract][Full Text] [Related]
18. p53 as a potential target in cancer therapy.
Ozturk M; Ponchel F; Puisieux A
Bone Marrow Transplant; 1992; 9 Suppl 1():164-70. PubMed ID: 1504661
[No Abstract] [Full Text] [Related]
19. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
Wawrzynow B; Zylicz A; Zylicz M
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
[TBL] [Abstract][Full Text] [Related]
20. Biological and clinical importance of the p53 tumor suppressor gene.
Velculescu VE; El-Deiry WS
Clin Chem; 1996 Jun; 42(6 Pt 1):858-68. PubMed ID: 8665676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]